Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Pfizer Beats Views Despite Slight Profit Decline

By Pharmaceutical Processing | February 1, 2011

NEW YORK (AP) — Pfizer Inc. said Tuesday its fourth-quarter
profit nearly quadrupled from a year ago when it was weighed down by
restructuring charges, as revenue rose 6 percent, thanks to the addition of
products from fellow drugmaker Wyeth, acquired late in 2009.

The results narrowly beat Wall Street expectations. Pfizer
also approved a $5 billion stock buyback plan and said it was cutting spending
on research and development.

Pfizer, the world’s biggest drugmaker by revenue, said its
net income was $2.89 billion, or 36 cents per share, compared with $767
million, or 10 cents per share, a year earlier.

Adjusted net income was $3.77 billion, or 47 cents per
share, down 1 percent from $3.83 billion a year earlier.

Revenue totaled $17.56 billion, up from $16.54 billion in
2009’s fourth quarter.

Analysts surveyed by FactSet were expecting earnings per
share of 46 cents and revenue of $16.99 billion.

The maker of cholesterol blockbuster Lipitor and impotence
pill Viagra reported a 3 percent increase in sales of its prescription drugs,
to $15.05 billion. Sales of veterinary medicines rose 8 percent, to $976
million, while the smaller consumer healthcare and nutrition businesses posted
larger jumps, due to the addition of those Wyeth businesses.

Pfizer bought Wyeth for $68 billion in October 2009, but
only recorded its revenue for part of that quarter.

Pfizer gave its first 2011 financial forecast, saying it
expects earnings per share of $2.16 to $2.26, excluding just over $1 in
one-time items. It expects revenue of $66 billion to $68 billion.

Analysts forecast earnings per share of $2.30 and revenue of
$66.55 billion, on average.

“I am pleased with our solid financial performance
again this quarter and this year despite continued challenging market
conditions,” new CEO Ian Read said in a statement.

Read took over after Pfizer’s board unexpectedly pushed out
CEO Jeffrey Kindler on Dec. 6, apparently due to the poor performance of
Pfizer’s stock and other issues during his 4 1/2-year tenure.

 

Related Articles Read More >

Astellas
Astellas to spend $70M on new biotech campus in South San Francisco
Rainin
Mettler Toledo Rainin expands facilities in Vacaville, California
Elemental Machines
Elemental Machines aims to enlist lab freezers in fight against climate change 
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards